| Date Filed | Type | Description |
| 05/26/2023 |
4
| Chevallard Daniel R. (CFO and COO) has filed a Form 4 on Viracta Therapeutics, Inc.|
Txns:
| Sold 3,635 shares
@ $1.4196, valued at
$5.2k
Exercised 6,889 restricted stock units
@ $0 |
|
| 05/26/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 03/17/2023 |
4
| Chevallard Daniel R. (CFO and COO) has filed a Form 4 on Viracta Therapeutics, Inc.|
Txns:
| Granted 200,000 options to buy
@ $1.65, valued at
$330k
|
|
| 02/28/2023 |
4
| Chevallard Daniel R. (CFO and COO) has filed a Form 4 on Viracta Therapeutics, Inc.|
Txns:
| Sold 3,599 shares
@ $1.6812, valued at
$6.1k
Exercised 6,889 restricted stock units
@ $0 |
|
| 11/29/2022 |
4
| Chevallard Daniel R. (CFO and COO) has filed a Form 4 on Viracta Therapeutics, Inc.|
Txns:
| Sold 3,532 shares
@ $2.7196, valued at
$9.6k
Exercised 6,889 restricted stock units
@ $0 |
|
| 08/29/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 05/27/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 03/18/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 03/01/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 11/30/2021 |
144
| Form 144 - Report of proposed sale of securities: |
| 11/29/2021 |
4
| Chevallard Daniel R. (CFO and COO) has filed a Form 4 on Viracta Therapeutics, Inc.|
Txns:
| Sold 3,254 shares
@ $4.8006, valued at
$15.6k
Sold 4,325 shares
@ $4.8191, valued at
$20.8k
Exercised 13,777 restricted stock units
@ $0 |
|
| 09/29/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/01/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 03/30/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/24/2021 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 07/02/2019 |
4
| Chevallard Daniel R. (CFO) has filed a Form 4 on Regulus Therapeutics Inc.|
Txns:
| Sold 2,669 shares
@ $1.3115, valued at
$3.5k
|
|
| 05/16/2019 |
4/A
| Chevallard Daniel R. (CFO) has filed a Form 4 on Regulus Therapeutics Inc.|
Txns:
| Granted 8,000 options to buy
@ $0.95, valued at
$7.6k
|
|
| 05/16/2019 |
4
| Chevallard Daniel R. (CFO) has filed a Form 4 on Regulus Therapeutics Inc.|
Txns:
| Granted 55,414 shares
@ $0
Sold 10,000 shares
@ $1.4089, valued at
$14.1k
Granted 8,000 options to buy
@ $0.95, valued at
$7.6k
|
|
| 04/03/2019 |
4
| Chevallard Daniel R. (CFO) has filed a Form 4 on Regulus Therapeutics Inc.|
Txns:
| Sold 3,253 shares
@ $0.9814, valued at
$3.2k
|
|
| 02/06/2019 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 05/21/2018 |
4
| Chevallard Daniel R. (CFO) has filed a Form 4 on Regulus Therapeutics Inc.|
Txns:
| Granted 250,000 options to buy
@ $0.71, valued at
$177.5k
|
|
| 01/05/2018 |
4
| Chevallard Daniel R. (CFO) has filed a Form 4 on Regulus Therapeutics Inc.|
Txns:
| Granted 350,000 options to buy
@ $1.24, valued at
$434k
|
|
| 07/25/2017 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 05/12/2017 |
4
| Chevallard Daniel R. (CFO) has filed a Form 4 on Regulus Therapeutics Inc.|
Txns:
| Granted 100,000 options to buy
@ $1.65, valued at
$165k
|
|
| 05/10/2017 |
3
| Chevallard Daniel R. (CFO) has filed a Form 3 on Regulus Therapeutics Inc. |